Pfizer PFE, +0.75% is already laying the groundwork for what the pharmaceutical behemoth will look like when revenue from its outsized COVID-19 vaccine and treatment franchise begins to wane.
“People are tired after three years of living very different, difficult lives,” Pfizer CEO Albert Bourla told MarketWatch. “So it’s clear that we will start seeing more and more waves. When people are wearing masks, when they are not having to provide guarantees that they are vaccinated or not, there will be waves. I don’t know if that will happen in the fall or it will happen in a different time in the U.S. because we have been surprised. But it will happen.
Moderna’s MRNA, +5.81% leadership has instead predicted that the bulk of its COVID-19 vaccine sales will occur in the second half of the year, timed to a fall booster campaign in the Western Hemisphere. “We continue to expect many more transactions from Pfizer over the next couple of years as management works to boost their pipeline and product portfolio,” Mizuho Securities analyst Vamil Divan told investors.“We are sourcing innovation also from the external and then we develop it internally,” Bourla said. “We are strong believers that the company that would become the partner of choice for biotech is the company that would give the next breakthroughs.
Why wouldn't they? We set the bar pretty low for them.
They should give the money back! The vaccine doesn’t even work as advertised. 🤡🤡
Feel Bitcoin is too risky to invest in? Then you haven't gotten the right information, I'm willing to show 10 lucky people how to earn 1 BC($41,910) and more daily- interested only persons should kindly send us a DM to get started